lurbinectedin


( Last Updated : August 4, 2022)
Generic Name:
lurbinectedin
Project Status:
Active
Therapeutic Area:
metastatic small cell lung cancer (SCLC)
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Zepzelca
Project Line:
Reimbursement Review
Project Number:
PC0281-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC

Details

Manufacturer Requested Reimbursement Criteria1:
Treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Lung
Indications:
Treatment of adult patients with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestones2

Call for patient/clinician input open26-Jan-22
Call for patient/clinician input closed18-Mar-22
Clarification:

- Patient input submission received from Lung Cancer Canada, and Lung Health Foundation / The Ontario Lung Association

Submission received24-Feb-22
Submission accepted10-Mar-22
Review initiated11-Mar-22
Draft CADTH review report(s) provided to sponsor for comment30-May-22
Deadline for sponsors comments08-Jun-22
CADTH review report(s) and responses to comments provided to sponsor30-Jun-22
Expert committee meeting (initial)13-Jul-22
Draft recommendation issued to sponsor26-Jul-22
Draft recommendation posted for stakeholder feedback04-Aug-22
End of feedback period18-Aug-22

Files

Recommendation and Reasons